|July 2010 · Vol. 22, No. 07
Why the FDA asked for more testing on flibanserin for HSDD
But the panel points to “widespread unmet need” for a medical therapy for HSDD in recommending that the drug maker continue to study the agent
Senior Editor, OBG Management
When the FDA Advisory Committee for Reproductive Health Drugs convened in mid-June to consider approving the nonhormonal agent flibanserin for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women, there was no FDA-approved drug for the disorder.
There still isn’t.